|
|
本帖最后由 douban 于 2016-8-27 12:00 编辑
7 e+ q _) U* g' W* A- ?8 V0 Q9 s* \( _0 L Z" H
Development of Novel Vaccines
4 A2 _3 }3 u5 U+ A5 f1 z9 i! K4 c6 c4 i
$ J: b+ |+ h" |2 d* d& ySkills, Knowledge and Translational Technologies2 V; `8 [' h$ b2 a3 x: [) d
$ s1 ]6 a4 Z8 {* [
Editors: von Gabain, Alexander, Klade, Christoph (Eds.)
! _/ z9 c1 j# e9 z. N7 n, z. V0 ` _
! Y9 A" E- k9 p$ Z4 Y+ E
2 P; a0 b) ]6 r( I6 S, u" e2 E$ T2 l9 \, Y- \, m! v* z3 }
About this book, {/ ?# R5 g/ T8 G4 n/ U
, s# r; X3 D% l2 Z
“Development of novel vaccines” gives an overview of the tasks in basic research leading to the final product – the vaccine and its applications, belonging to the most complex biologics in the pharmaceutical field. Distinct from most textbooks in the vaccine arena, the current issue focuses on the translational aspect, namely, how research results can be transformed into life-saving medical interventions. Each chapter of the book deals with one important paradigm for the development of novel vaccines, along the value chain towards the final vaccine, and furthermore, with the inevitable tools required for this process. Contributions are prepared by teams of scientists, all of whom are experts in the field, most of them anchored in biomedical organizations devoted to translational culture, thereby lighting the certain topics from different views. This volume is a must read for researchers engaged in vaccine development and who really want to see their research results to become a product.' k9 Z% F4 N3 ^# E. Y
$ G) Z6 J! _; U7 x' ~7 ?' j4 r+ z
& M! v* f4 o2 OTable of contents (11 chapters)9 y. e( p9 y9 y
8 N1 e. e/ y3 V; w
B4 w* o+ s9 n" ?3 g- ~Skills, Knowledge, and Translational Technologies Leading to Novel Vaccines
( g4 A$ W. K) [" i- O$ g$ J. _& f: D
! c5 t& Z0 |' I" U1 ZAlkan, Şefik Ş.
: f/ ?* R7 l4 U
$ Q4 ^0 v3 n8 S/ bPages 1-26
% L" ^* g% G/ _( @) z3 f- o* e; c( O1 W% l$ ]
Finding Protective Bacterial Antigens2 X, ^5 b' }: D+ @2 Q- Y
, _1 q: @4 ~" x& q0 KGrandi, Guido (et al.)' N* [+ ]8 M2 K
S# h+ B0 _ @+ `- E
Pages 27-44
3 f0 ^# e! `4 b T; h$ [
7 @4 c5 l, E' f
* S3 U7 K% l( E# _4 CEnhancing and Tailoring the Immunogenicity of Vaccines with Novel Adjuvants
: f# q2 c/ h6 Q
/ _, E( a* W5 ?% s2 `. {Fox, Christopher B. (et al.)/ C3 n: Q1 a6 I5 F! ]
& d: @% T3 k& v+ NPages 45-727 O, L; `9 I) W' c: \3 ]% A
' C" ?& _7 z) O9 |, z3 d: t3 H: q
' b7 s- S! w3 @4 R( o' \1 F1 e! v r0 ?
Vaccine Delivery: Beyond Needles' r8 ~$ w2 }, l3 i. a1 H, m. o
5 u9 x! h% \- v4 ]+ z2 X" D
Flyer, David C. (et al.)
6 `$ G% B+ u+ e4 V2 w2 `. Z/ `5 T9 ?- E1 ~4 t
Pages 73-86
; a. j) q/ H4 s) M
2 m1 R7 ^; ]- f' ?, R* Y8 d5 w) W; C+ J. n/ }! b& e3 \
% q6 M* N O6 B% l, E- _
Employing Live Microbes for Vaccine Delivery' L' C# \3 _; o
1 N5 ]; T/ w0 m2 X* ]& f1 q1 F! C2 B
Loessner, Holger (et al.)
& y% x1 T+ K( f( [8 s# Q3 c: T! r M- G; N9 _8 i, ]
Pages 87-124
3 O/ Q6 w( ]$ t5 _1 d+ z
$ Y g. H8 |! D/ y1 G ?; u7 O$ d2 @8 o* S; P( w! K
E# M# J8 q# j9 t: ZSynthesizing Vaccines with Microbes% S: T( ]1 {+ V, Z1 G2 Q0 d9 G
' L2 U( r9 z( r- J" t9 O- fWacker, Michael (et al.)
) ?9 e5 @% d- Y8 a( e* }9 B
% \4 X, T# j. j7 | V. ePages 125-144% M4 p3 I4 }6 [3 P/ Y8 X4 r0 e
# A& r# }( v/ I/ e- x( k
5 ]4 Y; p! d6 W8 }; m" T1 B. J( x; q7 Y |5 N
Purification and Formulation: Silent but Important Players in Vaccine Development
* K c8 e' V3 y8 ^/ y" w- ^- w$ s6 }# r2 Q3 e& h5 H
Schlegl, Robert (et al.)& I* {8 i4 t- n
8 r6 [' a S4 [7 E8 P6 V! ^1 aPages 145-1886 ]) ~8 D9 J/ }4 T4 ]& P+ C6 n2 \% N
! X5 D8 z- B6 u+ S' p
' ~% J* a6 G1 F2 ?/ x, n2 q" M( B* n, G, q- F: I# J
Cutting-Edge Approaches Toward Novel and Cross-Protective Influenza Vaccines
j: {4 B3 g( E
$ G2 ~2 c( y" N: P3 jArnon, Ruth (et al.)
1 C# I @, K" o* { V' L: k# H
5 ?* E* B3 x' Y ]8 e/ Z6 |, SPages 189-204; s" p9 c7 R* f7 z) I5 Q5 I6 A* r
+ m2 x1 M( I7 c* G2 H
1 V$ Q" g) V& `) b8 ~& B* h O/ W% L+ V* {2 J9 S! ]
Cutting Edge Approaches Toward Novel and Cross-Protective Influenza Vaccines
/ \ ~& I" G. g4 C& o/ k7 |3 B4 I5 W' t d+ J$ n9 K0 R* S
Roose, Kenny (et al.)
* M0 `* n% O; U X( J
* P, I- [' h, R8 dPages 205-232
7 b; u! S) \& K- Q5 X+ o' q
" M6 H( h9 R/ e5 {3 C! ]/ H. _6 u( Q$ P+ Z
, W" f- [ D; c# A' X5 f/ {9 H) k
Examples of Novel Registered Prophylactic Vaccines, HPV, and JEV
! W1 ?; M, O$ L
" x+ H- @ o8 D7 F/ w4 X6 GDubischar-Kastner, Katrin (et al.)
8 e9 W: n" U! W' b
9 G3 @3 \( a2 B9 q( u9 nPages 233-286+ n1 @& l/ Q( M k, m, I L9 ^
9 T2 N2 S4 q, h. K7 X; ?. }! l& `# l# n
/ f" V' _. p. u
The Bumpy Road Toward Vaccine Registration: How to Overcome Regulatory Hurdles& x! [1 e# e( k2 M# V, O
h; c1 a! u3 D3 D( \' q& OPfleiderer, Michael# D4 s* _ \) g) W; [+ R
% J0 |" }% i+ W. fPages 287-300
6 W) j6 U& _: G
8 D9 F- H9 b& X, O3 C+ M下载链接：
) g1 G1 ]3 _5 a: C6 x" ~
5 @8 ^& E9 N# f$ T6 z- h" M |
本帖子中包含更多资源
您需要 登录 才可以下载或查看，没有账号？立即注册
×
评分
-
查看全部评分
|
发表于 2016-8-27 11:57:27
发表于 2016-8-27 12:54:55
